Research Analysts Offer Predictions for ESPR Q4 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Stock analysts at Zacks Research boosted their Q4 2026 earnings per share (EPS) estimates for Esperion Therapeutics in a research report issued to clients and investors on Tuesday, March 31st. Zacks Research analyst Team now forecasts that the biopharmaceutical company will earn $0.04 per share for the quarter, up from their prior forecast of $0.03. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share. Zacks Research also issued estimates for Esperion Therapeutics’ Q1 2027 earnings at $0.06 EPS, Q2 2027 earnings at $0.10 EPS and FY2028 earnings at $0.39 EPS.

Other analysts have also issued reports about the stock. HC Wainwright restated a “buy” rating on shares of Esperion Therapeutics in a research note on Tuesday, March 10th. Wall Street Zen upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, March 14th. Citizens Jmp raised their price target on shares of Esperion Therapeutics from $4.00 to $5.00 and gave the company a “market outperform” rating in a research report on Friday, March 13th. Needham & Company LLC boosted their price objective on shares of Esperion Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Esperion Therapeutics in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Esperion Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $7.60.

Esperion Therapeutics Price Performance

Shares of Esperion Therapeutics stock opened at $2.61 on Wednesday. Esperion Therapeutics has a 1 year low of $0.69 and a 1 year high of $4.18. The firm’s 50-day moving average is $3.08 and its 200 day moving average is $3.16. The stock has a market cap of $670.27 million, a price-to-earnings ratio of -15.35, a PEG ratio of 1.97 and a beta of 1.17.

Esperion Therapeutics (NASDAQ:ESPR) last released its earnings results on Tuesday, March 10th. The biopharmaceutical company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.23 by ($0.01). The business had revenue of $168.45 million during the quarter, compared to analyst estimates of $165.12 million.

Institutional Investors Weigh In On Esperion Therapeutics

A number of hedge funds have recently added to or reduced their stakes in ESPR. R Squared Ltd boosted its stake in shares of Esperion Therapeutics by 23.5% in the 4th quarter. R Squared Ltd now owns 15,173 shares of the biopharmaceutical company’s stock worth $56,000 after buying an additional 2,890 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in Esperion Therapeutics by 10.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 38,955 shares of the biopharmaceutical company’s stock valued at $144,000 after acquiring an additional 3,614 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Esperion Therapeutics by 49.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,617 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 3,822 shares during the period. Eaton Financial Holdings Company LLC lifted its holdings in Esperion Therapeutics by 9.4% in the fourth quarter. Eaton Financial Holdings Company LLC now owns 46,595 shares of the biopharmaceutical company’s stock valued at $172,000 after acquiring an additional 4,000 shares during the period. Finally, Wealth Enhancement Advisory Services LLC boosted its position in Esperion Therapeutics by 18.5% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 28,338 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 4,422 shares during the last quarter. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.